Bando, Hideaki
Kotani, Daisuke
Tsushima, Takahiro
Hara, Hiroki
Kadowaki, Shigenori
Kato, Ken
Chin, Keisho
Yamaguchi, Kensei
Kageyama, Shun-ichiro
Hojo, Hidehiro
Nakamura, Masaki
Tachibana, Hidenobu
Wakabayashi, Masashi
Fukutani, Miki
Togashi, Yosuke
Fuse, Nozomu
Nishikawa, Hiroyoshi
Kojima, Takashi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (18ck0106420h0001)
Chugai Pharmaceutical
Article History
Received: 10 January 2020
Accepted: 5 March 2020
First Online: 20 April 2020
Ethics approval and consent to participate
: We are conducting this study in accordance with the guidelines for Good Clinical Practice of the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, as well as with the ethical guidelines for medical and health research involving human subjects. This study was approved by the ethics committees at each institution (National Cancer Center Institutional Review Board, Aichi Cancer Center Institutional Review Board, Saitama Cancer Center Review Board, Shizuoka Cancer Center Review Board, Cancer Institute Hospital of Japanese Foundation for Cancer Research Review Board). All patients are required to sign written informed consents.
: Not applicable.
: HB reports research funding from AstraZeneca and Sysmex, and honoraria from Taiho. DK reports receiving honoraria from Takeda, Chugai, Lilly, Merck Biopharma, Taiho, and Sysmex. TT reports no competing interests. HH reports paid consulting or advisory roles for Chugai, Merck Biopharma, Ono and MSD; honoraria from Chugai, Taiho, Merck Biopharma, Yakult, Lilly, Takeda, Bristol-Myers Squibb, Sanofi, Ono and MSD; and research funding from Astellas, AstraZeneca, Merck Biopharma, Takeda, Boehringer Ingelheim, Lilly, Ono, Sumitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD, Pfizer, Incyte, Beigene, LSK BioPharma and Eisai. SK reports research funding from Taiho, Lilly, and Ono, and honoraria from Taiho, Lilly, Ono, Bristol-Myers Squibb, Yakult, Chugai, Bayer, and Merck BioPharma. KK and KC reports no competing interests. KY, SK, and HH reports no competing interests. MN reports personal fees from MSD and AstraZeneca. HT, MW, and MF report no competing interests. YT reports honoraria from Ono, Bristol-Myers Squibb, Chugai, MSD, and AstraZeneca. NF and HN reports no competing interests. TK reports paid consulting or advisory roles for Bristol-Myers Squibb, honoraria from Oncolys BioPharma, and research funding from Ono, MSD, Oncolys BioPharma, Sihonogi, Chugai and Astellas Amgen BioPharma.